| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.45▼ | 3.39▲ | 3.40▲ | 3.25▲ | 3.15▲ |
| MA10 | 3.42▲ | 3.39▲ | 3.39▲ | 3.17▲ | 2.81▲ |
| MA20 | 3.39▲ | 3.39▲ | 3.29▲ | 3.12▲ | 2.63▲ |
| MA50 | 3.33▲ | 3.22▲ | 3.18▲ | 2.74▲ | 4.43▼ |
| MA100 | 3.22▲ | 3.15▲ | 3.12▲ | 2.55▲ | N/A |
| MA200 | 3.15▲ | 3.11▲ | 2.97▲ | 3.20▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | -0.005▼ | 0.008▲ | 0.014▲ | 0.282▲ |
| RSI | 59.205▲ | 64.468▲ | 65.178▲ | 75.757▲ | 52.027▲ |
| STOCH | 78.333 | 71.079 | 69.367 | 70.333 | 86.835▲ |
| WILL %R | -22.222▲ | -12.121▲ | -15.000▲ | -20.370▲ | -7.914▲ |
| CCI | 91.384 | 120.949▲ | 70.946 | 257.648▲ | 138.161▲ |
|
Monday, August 18, 2025 06:56 AM
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 19/08/25 | 3.43 | 3.46 | 3.33 | 3.43 | 78,483 |
| 18/08/25 | 3.07 | 3.54 | 3.046 | 3.41 | 218,875 |
| 15/08/25 | 3.15 | 3.17 | 3.06 | 3.14 | 58,700 |
| 14/08/25 | 3.07 | 3.13 | 3.0211 | 3.12 | 64,868 |
| 13/08/25 | 3.16 | 3.22 | 3.065 | 3.13 | 77,900 |
| 12/08/25 | 3.07 | 3.20 | 3.03 | 3.18 | 103,200 |
| 11/08/25 | 3.03 | 3.10 | 3.025 | 3.06 | 50,600 |
| 08/08/25 | 3.08 | 3.08 | 3.05 | 3.07 | 73,032 |
| 07/08/25 | 3.05 | 3.09 | 3.05 | 3.06 | 98,700 |
| 06/08/25 | 3.05 | 3.10 | 3.00 | 3.10 | 141,562 |
|
|
||||
|
|
||||
|
|